Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Study to Evaluate the Safety and Efficacy of GST-HG131 Tablets in Patients With Chronic Hepatitis B

NCT06263959 is registered in ClinicalTrials.gov with Fujian Akeylink Biotechnology Co., Ltd. as lead sponsor.

NCT NCT06263959
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06263959 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Study to Evaluate the Safety and Efficacy of GST-HG131 Tablets in Patients With Chronic Hepatitis B
Lead sponsor
Fujian Akeylink Biotechnology Co., Ltd.
Phase
Phase 2
Overall status
Recruiting
Start date
December 26, 2023
Completion date
May 1, 2025
Enrollment
45 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis b